Actinium Pharmaceuticals’ (ATNM) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a report issued on Monday, Benzinga reports. HC Wainwright currently has a $50.00 target price on the biotechnology company’s stock. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q2 2024 earnings at ($0.38) EPS, Q3 2024 earnings at ($0.45) EPS, Q4 2024 earnings at ($0.48) EPS, FY2024 earnings at ($1.61) EPS, FY2025 earnings at $1.21 EPS, FY2026 earnings at $4.10 EPS, FY2027 earnings at $7.94 EPS and FY2028 earnings at $10.75 EPS.

Other equities research analysts also recently issued research reports about the company. StockNews.com downgraded Actinium Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, March 19th. Maxim Group increased their price target on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a buy rating in a research report on Tuesday, March 19th. Finally, Cantor Fitzgerald restated an overweight rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus target price of $25.72.

Actinium Pharmaceuticals Trading Up 1.3 %

Shares of Actinium Pharmaceuticals stock opened at $7.80 on Monday. Actinium Pharmaceuticals has a 52 week low of $4.00 and a 52 week high of $9.86. The stock has a market capitalization of $232.28 million, a price-to-earnings ratio of -4.56 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last announced its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.21. The business had revenue of $0.08 million during the quarter. As a group, analysts predict that Actinium Pharmaceuticals will post -1.87 earnings per share for the current year.

Institutional Trading of Actinium Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ATNM. Brandywine Global Investment Management LLC bought a new position in Actinium Pharmaceuticals in the 3rd quarter worth $1,033,000. Sanders Morris Harris LLC bought a new position in shares of Actinium Pharmaceuticals in the first quarter worth about $78,000. Finally, Creative Financial Designs Inc. ADV lifted its position in shares of Actinium Pharmaceuticals by 19.1% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock worth $101,000 after purchasing an additional 3,175 shares during the last quarter. 27.50% of the stock is currently owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.